![]() Characteristics of Hospitalizations Among Pregnant People With COVID-19–Like Illness Who Did Not Have a Prior Positive SARS-CoV-2 Infection by COVID-19 mRNA Vaccination Status, VISION Network, 10 States, June 1, 2021–June 2, 2022ĮTable 9. Characteristics of Emergency Department and Urgent Care Encounters Among Nonpregnant Women Aged 18 to 45 Years With COVID-19–Like Illness by COVID-19 BNT162b2 Vaccination Status and SARS-CoV-2 Test Result, 10 States, June 1, 2021, to June 2, 2022ĮTable 8. Characteristics of COVID-19–Like Illness Hospitalizations Among Nonpregnant Women Aged 18 to 45 Years With COVID-19–Like Illness by COVID-19 BNT162b2 Vaccination Status and SARS-CoV-2 Test Result, 10 States, June 1, 2021, to June 2, 2022ĮTable 7. Characteristics of Emergency Department and Urgent Care Encounters Among Pregnant People With COVID-19–Like Illness by COVID-19 mRNA Vaccination Status (Regardless of Pregnancy Status at Time of Vaccination) and SARS-CoV-2 Test Result, 10 States, June 1, 2021, to June 2, 2022ĮTable 6. Characteristics of Hospitalizations Among Pregnant People With COVID-19–Like Illness by COVID-19 mRNA Vaccination Status (Regardless of Pregnancy Status at Time of Vaccination) and SARS-CoV-2 Test Result, 10 States, June 1, 2021, to June 2, 2022ĮTable 5. VISION Partner Site-Specific Start Dates for Delta and Omicron Predominance and Geographic RegionĮTable 4. Acute COVID-19–Like Illness Categories and Related International Classification of Diseases, 9th and 10th Revision ( ICD) Discharge Codes for Hospitalization and ED/UC VisitsĮTable 3. VISION Network Site Methods for Ascertainment of Gestational Age at Vaccination and the CLI Event and Whether the CLI Event Was Associated With DeliveryĮTable 2. CLI indicates COVID-19–like illness.ĮTable 1. VE could not be calculated for the individuals during the Delta period who received 3 doses of mRNA vaccine 120 or more days prior to hospitalization because the stratum included fewer than 20 encounters with prior vaccination. VE was calculated as described in the Methods section. Among vaccinated nonpregnant women with 3 doses, 130 in the Delta period and 43 in the Omicron period received the third dose less than 150 days after the second dose. Vaccinated pregnant people included in this analysis received at least their most recent dose during pregnancy among individuals with 3 doses, only 2 received the third dose less than 150 days after the second dose. The VISION Network includes Baylor Scott & White Health (Texas), Columbia University Irving Medical Center (New York), HealthPartners (Minnesota and Wisconsin), Intermountain Healthcare (Utah), Kaiser Permanente Northern California (California), Kaiser Permanente Northwest (Oregon and Washington), Regenstrief Institute (Indiana), and University of Colorado (Colorado). ![]() VE could not be calculated for vaccination during pregnancy during the Delta period among individuals who received 3 doses of mRNA vaccine 120 or more days because the stratum included fewer than 20 encounters with prior vaccination. Among vaccinated nonpregnant people with 3 doses, 273 in the Delta period and 324 in the Omicron period received the third dose less than 150 days after the second dose. ![]() Vaccinated pregnant people included in this analysis received at least their most recent dose during pregnancy among those with 3 doses, 3 participants during Delta and 1 during Omicron received dose 3 less than 150 days after dose 2, and none of these 4 had documented immunocompromised status. Kindly access the Agenda attached to this email.The VISION Network includes Baylor Scott & White Health (Texas), Columbia University Irving Medical Center (New York), HealthPartners (Minnesota and Wisconsin), Intermountain Healthcare (Utah), Kaiser Permanente Northern California (California), Kaiser Permanente Northwest (Oregon and Washington), Regenstrief Institute (Indiana), and University of Colorado (Colorado). The Workshop will be held on April 12 th, 2023 via Zoomstarting from 11:00 AM Central European Time (CET) for two hours, including a presentation, poll session, live streaming at Sartorius Application Center (Bangalore), and a Q&A session. Mishra, Rok Sekirnik, Buwadas Raut, Vinay Prathap, Loganathan Thangaselvam, Niveditha Shetty, Balaji S. Presented by Raman Rani, Niddhivinayak S. Sartorius Workshop – Accelerate mRNA Vaccines from Development to Commercialization
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |